medigraphic.com
Colegio de Medicina Interna de México.

2024, Number 07

<< Back Next >>

Med Int Mex 2024; 40 (07)

Myocarditis caused by immune checkpoint inhibitors: the future is today

Trujillo FD, Balderas GFL, Hernández VRO

Language: Spanish
References: 126
Page: 413-429
PDF size: 335.94 Kb.


ABSTRACT

Background: Myocarditis due to the use of immune checkpoint inhibitors is a potentially fatal complication in the management of patients with advanced neoplastic disease, which has been increasingly reported worldwide due to the untamed evolution of chemotherapy.
Objectives: Describe the epidemiology, pathophysiology, timely detection, clinical picture, diagnosis and treatment of myocarditis due to immune checkpoint inhibitors.
Methodology: An exhaustive search was carried out in various databases: PubMed, Google Scholar and ClinicalKey. Articles in English published from 2002 to 2023 were selected. Terms were used according to the MeSH scheme: Immune checkpoint inhibitors, myocarditis, adverse event related to the immune system.
Results: A total of 899 articles were obtained, of which 126 were selected, which include notable literature reviews, observational studies, systematic reviews, metaanalyses, randomized clinical trials, patient registries and international clinical practice guidelines. The rest of the articles were excluded because they did not meet the objectives of the review.
Conclusions: Timely diagnosis of this immune-mediated complication will allow prompt treatment.


REFERENCES

  1. Haslam A, Prasad V. Estimation of the percentage of USpatients with cancer who are eligible for and respondto checkpoint inhibitor immunotherapy drugs. JAMANetw Open 2019; 2 (5): e192535. doi: 10.1001/jamanetworkopen. 2019.2535

  2. Zaha VG, Meijers WC, Moslehi J. Cardio-immuno-oncology.Circulation 2020; 141 (2): 87-9. doi: 10.1161/CIRCULATIONAHA.119.042276

  3. Bertrand A, Kostine M, Barnetche T, Truchetet ME,Schaeverbeke T. Immune related adverse events associatedwith anti-CTLA-4 antibodies: systematic review andmeta-analysis. BMC Med 2015; 13: 211. doi: 10.1186/s12916-015-0455-8

  4. Palmieri DJ, Carlino MS. Immune checkpoint inhibitortoxicity. Curr Oncol Rep 2018; 20 (9): 72. doi: 10.1007/s11912-018-0718-6

  5. Dong M, Yu T, Zhang Z, Zhang J, et al. ICIs-related cardiotoxicityin different types of cancer. J Cardiovasc Dev Dis2022; 9 (7): 203. doi: 10.3390/jcdd9070203

  6. Ball S, Ghosh RK, Wongsaengsak S, Bandyopadhyay D, et al.Cardiovascular toxicities of immune checkpoint inhibitors:JACC review topic of the week. J Am Coll Cardiol 2019; 74(13): 1714-27. doi: 10.1016/j.jacc.2019.07.079

  7. Balanescu DV, Donisan T, Palaskas NL, Iliescu C. Emergingconcerns in cardio-oncology: immune checkpoint inhibitorcardiotoxicity. Am Coll Cardiol 2019.

  8. Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, et al.Relatlimab and nivolumab versus nivolumab in untreatedadvanced melanoma. N Engl J Med 2022; 386 (1): 24-34.doi: 10.1056/NEJMoa2109970

  9. Ganatra S, Neilan TG. Immune checkpoint inhibitor associatedmyocarditis. Oncologist 2018; 23 (8): 879-86. doi:

  10. 10.1634/theoncologist.2018-013010. Postow MA, Sidlow R, Hellmann MD. Immunerelatedadverse events associated with immune checkpoint blockade.N Engl J Med 2018; 378 (2): 158-68. doi: 10.1056/NEJMra1703481

  11. Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B,Bastarache L, et al. Cardiovascular toxicities associated withimmune checkpoint inhibitors: an observational, retrospective,pharmacovigilance study. Lancet Oncol 2018; 19 (12):1579-89. doi: 10.1016/S1470-2045(18)30608-9

  12. Mahmood SS, Fradley MG, Cohen JV, Nohria A, et al.Myocarditis in patients treated with immune checkpointinhibitors. J Am Coll Cardiol 2018; 71 (16): 1755-64. doi:10.1016/S0735-1097 (18)31240-3

  13. Oren O, Yang EH, Molina JR, Bailey KR, et al. CardiovascularHealth and Outcomes in Cancer Patients Receiving ImmuneCheckpoint Inhibitors. Am J Cardiol 2020; 125 (12): 1920-26. doi: 10.1016/j.amjcard.2020.02.016

  14. Wang DY, Salem JE, Cohen JV, Chandra S, et al. Fatal toxiceffects associated with immune checkpoint inhibitors: Asystematic review and meta-analysis. JAMA Oncol 2018; 4(12): 1721-28. doi: 10.1001/jamaoncol.2018.3923

  15. Conforti F, Pala L, Bagnardi V, De Pas T, et al. Cancer immunotherapyefficacy and patients’ sex: a systematic reviewand meta-analysis. Lancet Oncol 2018; 19 (6): 737-46. doi:10.1016/S1470-2045(18)30261-4

  16. Toi Y, Sugawara S, Sugisaka J, Ono H, et al. Profiling preexistingantibodies in patients treated with anti-PD-1 therapyfor advanced non-small cell lung cancer. JAMA Oncol 2019;5 (3): 376-83. doi: 10.1001/jamaoncol.2018.5860

  17. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, etal. Anti-PD-1 therapy in patients with advanced melanomaand preexisting autoimmune disorders or major toxicitywith ipilimumab. Ann Oncol 2017; 28 (2): 368-76. doi:10.1093/annonc/mdw443

  18. Guha A, Al-Kindi S, Jain P, Tashtish N, et al. Associationbetween myocarditis and other immune-related adverseevents secondary to immune checkpoint inhibitor use. IntJ Cancer 2020; 147 (6): 1753-54. doi: 10.1002/ijc.32960

  19. Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, etal. Smoldering myocarditis following immune checkpointblockade. J Immunother Cancer 2017; 5 (1): 91. doi:10.1186/s40425-017-0296-4

  20. Lichtman AH. The heart of the matter: protection of themyocardium from T cells. J Autoimmun 2013; 45: 90-6. doi:10.1016/j.jaut.2013.05.004

  21. Bluestone JA, Anderson M. Tolerance in the age of immunotherapy.N Engl J Med 2020; 383 (12): 1156-66. doi:10.1056/NEJMra1911109

  22. Mueller DL. Mechanisms maintaining peripheral tolerance.Nat Immunol 2010; 11 (1): 21-7. doi: 10.1038/ni.1817

  23. Macián F, García-Cózar F, Im SH, Horton HF, et al. Transcriptionalmechanisms underlying lymphocyte tolerance. Cell2002; 109 (6): 719-31. doi: 10.1016/s0092-8674(02)00767-5

  24. Riella LV, Paterson AM, Sharpe AH, Chandraker A. Roleof the PD-1 pathway in the immune response. Am JTransplant 2012; 12 (10): 2575-87. doi: 10.1111/j.1600-6143.2012.04224.x

  25. Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA.CD28 costimulation: From mechanism to therapy. Immunity2016; 44 (5): 973-88. doi: 10.1016/j.immuni.2016.04.020

  26. Boussiotis VA. Molecular and biochemical aspects of thePD-1 checkpoint pathway. N Engl J Med 2016; 375 (18):1767-78. doi: 10.1056/NEJMra1514296

  27. Zhou YW, Zhu YJ, Wang MN, Xie Y, et al. Immunecheckpointinhibitor-associated cardiotoxicity: current understandingon its mechanism, diagnosis and management. FrontPharmacol 2019; 10: 1350. doi: 10.3389/fphar.2019.01350

  28. Wang Z, Wu X. Study and analysis of antitumor resistancemechanism of PD1/PD-L1 immune checkpoint blocker. CancerMed 2020; 9 (21): 8086-121. doi: 10.1002/cam4.3410

  29. Gianchecchi E, Delfino DV, Fierabracci A. Recent insightsinto the role of the PD-1/PD-L1 pathway in immunologicaltolerance and autoimmunity. Autoimmun Rev 2013; 12(11): 1091-100. doi: 10.1016/j.autrev.2013.05.003

  30. Grabie N, Lichtman AH, Padera R. T cell checkpoint regulatorsin the heart. Cardiovasc Res 2019; 115 (5): 869-77. doi:10.1093/cvr/cvz025

  31. Hanahan D. Hallmarks of cancer: New dimensions. CancerDiscov 2022; 12 (1): 31-46. doi: 10.1158/2159-8290.CD-21-1059

  32. Stein-Merlob AF, Rothberg MV, Ribas A, Yang EH. Cardiotoxicitiesof novel cancer immunotherapies. Heart 2021;107 (21): 1694-1703. doi: 10.1136/heartjnl-2020-318083

  33. Wang D, Bauersachs J, Berliner D. Immune checkpointinhibitor associated myocarditis and cardiomyopathy: Atranslational review. Biology (Basel) 2023; 12 (3): 472. doi:10.3390/biology12030472

  34. Tajiri K, Aonuma K, Sekine I. Immune checkpoint inhibitorrelatedmyocarditis. Jpn J Clin Oncol 2018; 48 (1): 7-12. doi:10.1093/jjco/hyx154

  35. Grabie N, Gotsman I, DaCosta R, Pang H, et al. Endothelialprogrammed death-1 ligand 1 (PD-L1) regulates CD8+ Tcellmediated injury in the heart. Circulation 2007; 116(18): 2062-71. doi: 10.1161/CIRCULATIONAHA.107.709360

  36. Reuben A, Petaccia de Macedo M, McQuade J, Joon A,Ren Z, Calderone T, et al. Comparative immunologic characterizationof autoimmune giant cell myocarditis withipilimumab. Oncoimmunology 2017; 6 (12): e1361097.doi: 10.1080/2162402X.2017.1361097

  37. Johnson DB, Balko JM, Compton ML, Chalkias S, et al Fulminantmyocarditis with combination immune checkpointblockade. N Engl J Med 2016; 375 (18): 1749-55. doi:10.1056/NEJMoa1609214

  38. Franciszkiewicz K, Boissonnas A, Boutet M, CombadièreC, Mami-Chouaib F. Role of chemokines and chemokinereceptors in shaping the effector phase of the antitumorimmune response. Cancer Res 2012; 72 (24): 6325-32. doi:10.1158/0008-5472.CAN-12-2027

  39. Tocchetti CG, Galdiero MR, Varricchi G. Cardiac toxicity inpatients treated with immune checkpoint inhibitors: It isnow time for cardio-immuno-oncology. J Am Coll Cardiol2018; 71 (16): 1765-67. doi: 10.1016/j.jacc.2018.02.038

  40. Zhang X, Gan Y, Zhu H, Liu Z, et al. Role of mitochondrialmetabolism in immune checkpoint inhibitors-related myocarditis.Front Cardiovasc Med 2023; 10: 1112222. doi:10.3389/fcvm.2023.1112222

  41. Wong CK, Lam TH, Liao SY, Lau YM, et al. Immunopathogenesisof immune checkpoint inhibitor induced myocarditis:Insights from experimental models and treatmentimplications. Biomedicines 2023; 11 (1): 107. doi: 10.3390/biomedicines11010107

  42. Brahmer JR, Lacchetti C, Thompson JA. Management ofimmune-related adverse events in patients treated withimmune checkpoint inhibitor therapy: American Society ofClinical Oncology Clinical Practice Guideline Summary. J OncolPract 2018; 14 (4): 247-49. doi: 10.1200/JOP.18.00005

  43. Furukawa A, Tamura Y, Taniguchi H, Kawamura A, et al.Prospective screening for myocarditis in cancer patientstreated with immune checkpoint inhibitors. J Cardiol 2023;81 (1): 63-7. doi: 10.1016/j.jjcc.2022.07.009

  44. Waliany S, Neal JW, Reddy S, Wakelee H, et al. Myocarditissurveillance with high-sensitivity troponin I during cancertreatment with immune checkpoint inhibitors. JACC CardioOncol2021; 3: 137-9. doi: 10.1016/j.jaccao.2021.01.004

  45. Pudil R, Mueller C, Čelutkienė J, Henriksen PA, et al. Role ofserum biomarkers in cancer patients receiving cardiotoxiccancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Associationand the Cardio-Oncology Council of the European Societyof Cardiology. Eur J Heart Fail 2020; 22 (11): 1966-83. doi:10.1002/ejhf.2017

  46. Celutkienė J, Pudil R, López-Fernández T, Grapsa J, etal. Role of cardiovascular imaging in cancer patientsreceiving cardiotoxic therapies: A Position Statement onBehalf of the Heart Failure Association (HFA), the EuropeanAssociation of Cardiovascular Imaging (EACVI) andthe Cardio-Oncology Council of the European Society ofCardiology (ESC). Eur J Heart Fail 2020; 22 (9): 1504-24.doi: 10.1002/ejhf.1957

  47. Osinga TE, Oosting SF, van der Meer P, de Boer RA, et al.Immune checkpoint inhibitor-associated myocarditis : Casereports and a review of the literature. Neth Heart J 2022;30 (6): 295-301. doi: 10.1007/s12471-021-01655-7

  48. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, etal. ESC Scientific Document Group. 2022 ESC Guidelineson cardio-oncology developed in collaboration with theEuropean Hematology Association (EHA), the EuropeanSociety for Therapeutic Radiology and Oncology (ESTRO)and the International Cardio-Oncology Society (IC-OS).Eur Heart J 2022; 43 (41): 4229-4361. doi: 10.1093/eurheartj/ehac244

  49. Rini BI, Moslehi JJ, Bonaca M, Schmidinger M, et al. Prospectivecardiovascular surveillance of immune checkpointinhibitor-based combination therapy in patients with advancedrenal cell cancer: Data from the Phase III JAVELINRenal 101 Trial. J Clin Oncol 2022; 40 (17): 1929-38. doi:10.1200/JCO.21.01806

  50. Thuny F, Alexandre J, Salem JE, Mirabel M, et al. Managementof immune checkpoint inhibitor-induced myocarditis:the French Working Group’s Plea for a pragmatic approach.JACC CardioOncol 2021; 3: 157-161. doi: 10.1016/j.jaccao.2020.12.001

  51. Zhang L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. Theevolving immunotherapy landscape and the epidemiology,diagnosis, and management of cardiotoxicity: JACC: CardioOncologyprimer. JACC CardioOncol 2021; 3 (1): 35-47.doi: 10.1016/j.jaccao.2020.11.012

  52. Atallah-Yunes SA, Kadado AJ, Kaufman GP, Hernandez-Montfort J. Immune checkpoint inhibitor therapy andmyocarditis: a systematic review of reported cases. J CancerRes Clin Oncol 2019; 145 (6): 1527-57. doi: 10.1007/s00432-019-02927-x

  53. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, et al.Combined nivolumab and ipilimumab or monotherapy inuntreated melanoma. N Engl J Med 2015; 373 (1): 23-34.doi: 10.1056/NEJMoa1504030

  54. Yamaguchi S, Morimoto R, Okumura T, Yamashita Y, et al.Late-onset fulminant myocarditis with immune checkpointinhibitor nivolumab. Can J Cardiol 2018; 34 (6): 812.e1-e3.doi: 10.1016/j.cjca.2018.03.007

  55. Caforio AL, Pankuweit S, Arbustini E, Basso C, et al. Currentstate of knowledge on aetiology, diagnosis, management,and therapy of myocarditis: a position statement of theEuropean Society of Cardiology Working Group on Myocardialand Pericardial Diseases. Eur Heart J 2013; 34 (33):2636-48, 2648a-2648d. doi: 10.1093/eurheartj/eht210

  56. Pradhan R, Nautiyal A, Singh S. Diagnosis of immunecheckpoint inhibitor-associated myocarditis: A systematicreview. Int J Cardiol 2019; 296: 113-21. doi: 10.1016/j.ijcard.2019.07.025

  57. Behling J, Kaes J, Munzel T, Grabbe S, Loquai C. Newonsetthird-degree atrioventricular block because ofautoimmune-induced myositis under treatment with antiprogrammedcell death-1 (nivolumab) for metastatic melanoma.Melanoma Res 2017; 27 (2): 155-8. doi: 10.1097/CMR.0000000000000314

  58. Amiri-Kordestani L, Moslehi J, Cheng J, Tang S, et al. Cardiovascularadverse events in immune checkpoint inhibitorclinical trials: a U.S. Food and Drug Administration pooledanalysis. J Clin Oncol 2018; 36.

  59. Michot JM, Bigenwald C, Champiat S, Collins M, et al.Immune-related adverse events with immune checkpointblockade: a comprehensive review. Eur J Cancer 2016; 54:139-48. doi: 10.1016/j.ejca.2015.11.016

  60. Ahmed T, Yadav RK, Abedin ZU, Cao X, et al Immune checkpointinhibitor-related acute myocarditis masquerading asacute coronary syndrome. Curr Probl Cardiol 2023; 48 (4):101577. doi: 10.1016/j.cpcardiol.2022.101577

  61. Herrmann J, Lenihan D, Armenian S, Barac A, et al. Definingcardiovascular toxicities of cancer therapies: anInternational Cardio-Oncology Society (IC-OS) consensusstatement. Eur Heart J 2022; 43 (4): 280-99. doi: 10.1093/eurheartj/ehab674

  62. Thuny F, Naidoo J, Neilan TG. Cardiovascular complicationsof immune checkpoint inhibitors for cancer. Eur Heart J2022; 43 (42): 4458-68. doi: 10.1093/eurheartj/ehac456

  63. Rossi S, Cani I, Raschi E, Comito F, et al. Neurological manifestationsas a harbinger of myocarditis in patients treatedwith immune checkpoint inhibitors. J Clin Oncol 2023; 41(5): 1151-53. doi: 10.1200/JCO.22.01602

  64. Bowyer S, Prithviraj P, Lorigan P, Larkin J, et al. Efficacyand toxicity of treatment with the anti-CTLA-4 antibodyipilimumab in patients with metastatic melanoma afterprior anti-PD-1 therapy. Br J Cancer 2016; 114 (10): 1084-9.doi: 10.1038/bjc.2016.107

  65. Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, et al.Myocarditis in the setting of cancer therapeutics: proposedcase definitions for emerging clinical syndromes in cardiooncology.Circulation 2019; 140 (2): 80-91. doi: 10.1161/CIRCULATIONAHA.118.034497

  66. Tamura Y, Tamura Y, Taniguchi H, Imanaka-Yoshida K. Acutemyocarditis after discontinuation of immune checkpointinhibitor therapy. Circ J 2023; 87 (2): 376. doi: 10.1253/circj.CJ-22-0613

  67. Puzanov I, Subramanian P, Yatsynovich YV, Jacobs DM,et al. Clinical characteristics, time course, treatment andoutcomes of patients with immune checkpoint inhibitorassociatedmyocarditis. J Immunother Cancer 2021; 9 (6):e002553. doi: 10.1136/jitc-2021-002553

  68. Hughes M, Lilleker JB, Herrick AL, Chinoy H. Cardiactroponin testing in idiopathic inflammatory myopathiesand systemic sclerosis-spectrum disorders: biomarkers todistinguish between primary cardiac involvement and lowgradeskeletal muscle disease activity. Ann Rheum Dis 2015;74 (5): 795-8. doi: 10.1136/annrheumdis-2014-206812

  69. Thibault C, Vano Y, Soulat G, Mirabel M. Immune checkpointinhibitors myocarditis: not all cases are clinicallypatent. Eur Heart J 2018; 39 (38): 3553. doi: 10.1093/eurheartj/ehy485

  70. Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, et al.Immune checkpoint inhibitor-associated myositis: expandingthe spectrum of cardiac complications of the immunotherapyrevolution. Circulation. 2018; 138 (7): 743-45. doi:10.1161/CIRCULATIONAHA.118.035898

  71. Isa M, Hongo Y, Sakamoto N, Yamazaki K, et al. Immunecheckpoint inhibitor-related myositis and myocarditis withmultiple myositis-specific/-associated antibodies. J NeurolSci 2023; 444: 120528. doi: 10.1016/j.jns.2022.120528

  72. Tang X, Li Y, Huang H, Shi R, et al. Early evaluation of severeimmune checkpoint inhibitor-associated myocarditis: areal-world clinical practice. J Cancer Res Clin Oncol 2023.doi: 10.1007/s00432-023-04782-3

  73. Longinow J, Zmaili M, Skoza W, Kondoleon N, et al. Immunecheckpoint inhibitor induced myocarditis, myasthenia gravis,and myositis: A single-center case series. Cancer Med2023; 12 (3): 2281-89. doi: 10.1002/cam4.5050

  74. Nierengarten MB. New biomarker-based strategy screensfor myocarditis after immune checkpoint inhibitor treatment.Cancer 2023; 129 (9): 1304. doi: 10.1002/cncr.34777

  75. Song W, Zheng Y, Dong M, Zhong L, et al. Electrocardiographicfeatures of immune checkpoint inhibitor-associatedmyocarditis. Curr Probl Cardiol 2023; 48 (2): 101478.doi: 10.1016/j.cpcardiol.2022.101478

  76. Lee Chuy K, Oikonomou EK, Postow MA, Callahan MK,et al. Myocarditis surveillance in patients with advancedmelanoma on combination immune checkpoint inhibitortherapy: The Memorial Sloan Kettering Cancer CenterExperience. Oncologist 2019; 25 (4): e196-7. doi: 10.1634/theoncologist.2019-0040

  77. Di Bella G, Florian A, Oreto L, Napolitano C, et al. Electrocardiographicfindings and myocardial damage in acutemyocarditis detected by cardiac magnetic resonance. ClinRes Cardiol 2012; 101 (8): 617-24. doi: 10.1007/s00392-012-0433-5

  78. Power JR, Alexandre J, Choudhary A, Ozbay B, et al. Electrocardiographicmanifestations of immune checkpointinhibitor myocarditis. Circulation 2021; 144 (23): 1521-23.doi: 10.1161/CIRCULATIONAHA.121.055816

  79. Zlotoff DA, Hassan MZO, Zafar A, Alvi RM, et al. Electrocardiographicfeatures of immune checkpoint inhibitorassociated myocarditis. J Immunother Cancer 2021; 9 (3):e002007. doi: 10.1136/jitc-2020-002007

  80. Yang S, Asnani A. Cardiotoxicities associated with immunecheckpoint inhibitors. Curr Probl Cancer 2018; 42 (4): 422-32. doi: 10.1016/j.currproblcancer.2018.07.002

  81. Moslehi JJ, Salem J-E, Sosman JA, Lebrun-Vignes B, JohnsonDB. Increased reporting of fatal immune checkpointinhibitor-associated myocarditis. Lancet 2018; 391 (10124):933. doi: 10.1016/S0140-6736(18)30533-6

  82. Armenian SH, Lacchetti C, Barac A, Carver J, et al. Preventionand monitoring of cardiac dysfunction in survivors ofadult cancers: American Society of Clinical Oncology ClinicalPractice Guideline. J Clin Oncol 2017; 35 (8): 893-911. doi:10.1200/JCO.2016.70.5400

  83. Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A.Immune checkpoint inhibitor myocarditis: pathophysiologicalcharacteristics, diagnosis, and treatment. J Am HeartAssoc 2020; 9 (2): e013757. doi: 10.1161/JAHA.119.013757

  84. Awadalla M, Mahmood SS, Groarke JD, Hassan MZO, et al.Global longitudinal strain and cardiac events in patientswith immune checkpoint inhibitor-related myocarditis.J Am Coll Cardiol 2020; 75 (5): 467-78. doi: 10.1016/j.jacc.2019.11.049

  85. Neilan TG, Rothenberg ML, Amiri-Kordestani L, SullivanRJ, et al. Checkpoint Inhibitor Safety Working Group.Myocarditis associated with immune checkpoint inhibitors:An Expert Consensus on Data Gaps and a Call to Action.Oncologist 2018; 23 (8): 874-78. doi: 10.1634/theoncologist.2018-0157

  86. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM,et al. Cardiovascular magnetic resonance in nonischemicmyocardial inflammation: expert recommendations. JAm Coll Cardiol 2018; 72 (24): 3158-76. doi: 10.1016/j.jacc.2018.09.072

  87. Wintersperger BJ, Calvillo-Argüelles O, Lheureux S, HouboisCP, et al. Immune checkpoint inhibitor-related myocarditis:an illustrative case series of applying the updated CardiovascularMagnetic Resonance Lake Louise Criteria. Eur Heart JCase Rep 2022; 6 (1): ytab478. doi: 10.1093/ehjcr/ytab478

  88. Zhang L, Awadalla M, Mahmood SS, Nohria A, et al. Cardiovascularmagnetic resonance in immune checkpointinhibitor-associated myocarditis. Eur Heart J 2020; 41 (18):1733-43. doi: 10.1093/eurheartj/ehaa051

  89. Zhang L, Awadalla M, Mahmood SS, Groarke J, et al. Lategadolinium enhancement in patients with myocarditis fromimmune checkpoint inhibitors. J Am Coll Cardiol 2019; 73 (9Supplement 1): 675. DOI:10.1016/S0735-1097(19)31283-5

  90. Thavendiranathan P, Zhang L, Zafar A, Drobni ZD, et al.Myocardial T1 and T2 mapping by magnetic resonancein patients with immune checkpoint inhibitor-associatedmyocarditis. J Am Coll Cardiol 2021; 77 (12): 1503-16. doi:10.1016/j.jacc.2021.01.050

  91. Aquaro GD, Perfetti M, Camastra G, Monti L, et al. CardiacMagnetic Resonance Working Group of the Italian Societyof Cardiology. Cardiac MR With late gadolinium enhancementin acute myocarditis with preserved systolic function:ITAMY Study. J Am Coll Cardiol 2017; 70 (16): 1977-87. doi:10.1016/j.jacc.2017.08.044

  92. Cadour F, Cautela J, Rapacchi S, Varoquaux A, et al. CardiacMRI features and prognostic value in immune checkpointinhibitor-induced myocarditis. Radiology 2022; 303 (3):512-21. doi: 10.1148/radiol.211765

  93. Ederhy S, Fenioux C, Cholet C, Rouvier P, et al. Immunecheckpoint inhibitor myocarditis with normal cardiacmagnetic resonance imaging: Importance of cardiac biopsyand early diagnosis. Can J Cardiol 2021; 37 (10): 1654-56.doi: 10.1016/j.cjca.2020.12.022

  94. Cau R, Solinas C, De Silva P, Lambertini M, et al. Roleof cardiac MRI in the diagnosis of immune checkpointinhibitor-associated myocarditis. Int J Cancer 2022; 151(11): 1860-73. doi: 10.1002/ijc.34169

  95. Collet JP, Thiele H, Barbato E, Barthélémy O, et al. ESCGuidelines for the management of acute coronarysyndromes in patients presenting without persistent STsegmentelevation. Eur Heart J 2021; 42 (14): 1289-1367.doi: 10.1093/eurheartj/ehaa575

  96. Bozkurt B, Colvin M, Cook J, Cooper LT, et al. Currentdiagnostic and treatment strategies for specific dilated cardiomyopathies:A scientific statement from the AmericanHeart Association. Circulation 2016; 134 (23): e579-e646.doi: 10.1161/CIR.0000000000000455

  97. Cooper LT, Baughman KL, Feldman AM, Frustaci A, et al.The role of endomyocardial biopsy in the managementof cardiovascular disease: a scientific statement fromthe American Heart Association, the American Collegeof Cardiology, and the European Society of CardiologyEndorsed by the Heart Failure Society of America and theHeart Failure Association of the European Society of Cardiology.Eur Heart J 2007; 28 (24): 3076-93. doi: 10.1093/eurheartj/ehm456.

  98. Aretz HT. Myocarditis: the Dallas criteria. Hum Pathol 1987;18 (6): 619-24. doi: 10.1016/s0046-8177(87)80363-5

  99. Palaskas NL, Segura A, Lelenwa L, Siddiqui BA, et al. Immunecheckpoint inhibitor myocarditis: elucidating thespectrum of disease through endomyocardial biopsy. EurJ Heart Fail 2021; 23 (10): 1725-35. doi: 10.1002/ejhf.2265

  100. Matson DR, Accola MA, Rehrauer WM, Corliss RF. Fatalmyocarditis following treatment with the PD-1 inhibitornivolumab. J Forensic Sci 2018; 63 (3): 954-57. doi:10.1111/1556-4029.13633

  101. Seferović PM, Tsutsui H, McNamara DM, Ristić AD, et alHeart Failure Association of the ESC, Heart Failure Societyof America and Japanese Heart Failure Society Positionstatement on endomyocardial biopsy. Eur J Heart Fail 2021;23 (6): 854-71. doi: 10.1002/ejhf.2190

  102. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, et al. Managementof immunerelated adverse events in patients treatedwith immune checkpoint inhibitor therapy: American Societyof Clinical Oncology Clinical Practice Guideline. J Clin Oncol2018; 36: 1714-68. doi: 10.1200/JCO.2017.77.6385

  103. Kociol RD, Cooper LT, Fang JC, Moslehi JJ, et al. Recognitionand initial management of fulminant myocarditis:A scientific statement from the American Heart Association.Circulation 2020; 141 (6): e69-e92. doi: 10.1161/CIR.0000000000000745

  104. Haanen JBAG, Carbonnel F, Robert C, Kerr KM, et al. Managementof toxicities from immunotherapy: ESMO ClinicalPractice Guidelines for diagnosis, treatment and follow-up.Ann Oncol 2017; 28 (suppl_4): iv119-iv142. doi: 10.1093/annonc/mdx225

  105. Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, et al. Societyfor Immunotherapy of Cancer (SITC) clinical practiceguideline on immune checkpoint inhibitor-related adverseevents. J Immunother Cancer 2021; 9 (6): e002435. doi:10.1136/jitc-2021-002435

  106. Haanen J, Obeid M, Spain L, Carbonnel F, et al. Managementof toxicities from immunotherapy: ESMO ClinicalPractice Guideline for diagnosis, treatment and followup.Ann Oncol 2022; 33 (12): 1217-38. doi: 10.1016/j.annonc.2022.10.001

  107. Zhang L, Zlotoff DA, Awadalla M, Mahmood SS, et al. Majoradverse cardiovascular events and the timing and dose ofcorticosteroids in immune checkpoint inhibitor-associatedmyocarditis. Circulation 2020; 141 (24): 2031-34. doi:10.1161/CIRCULATIONAHA.119.044703

  108. Waliany S, Lee D, Witteles RM, Neal JW, et al. Immunecheckpoint inhibitor cardiotoxicity: Understanding basicmechanisms and clinical characteristics and finding acure. Annu Rev Pharmacol Toxicol 2021; 61: 113-34. doi:10.1146/annurev-pharmtox-010919-023451

  109. Herrmann J. Adverse cardiac effects of cancer therapies:cardiotoxicity and arrhythmia. Nat Rev Cardiol 2020; 17(8): 474-502. doi: 10.1038/s41569-020-0348-1

  110. Wang C, Lin J, Wang Y, Hsi DH, et al. Case series ofsteroid-resistant immune checkpoint inhibitor associatedmyocarditis: as comparative analysis of corticosteroid andtofacitinib treatment. Front Pharmacol 2021; 12: 770631.doi: 10.3389/fphar.2021.770631

  111. Cautela J, Zeriouh S, Gaubert M, Bonello L, et al. Intensifiedimmunosuppressive therapy in patients withimmune checkpoint inhibitor-induced myocarditis. JImmunother Cancer 2020; 8 (2): e001887. doi: 10.1136/jitc-2020-001887

  112. Dougan M. Weighing antitumor immunity againstlife-threatening myocarditis from immune-checkpointinhibitors. Cancer Discov 2023; 13 (5): 1040-42. doi:10.1158/2159-8290.CD-23-0199

  113. Champion SN, Stone JR. Immune checkpoint inhibitor associatedmyocarditis occurs in both high-grade and low-gradeforms. Mod Pathol 2020; 33 (1): 99-108.

  114. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, et al.Management of immune-related adverse events in patientstreated with immune checkpoint inhibitor therapy: ASCOguideline update. J Clin Oncol 2021; 39 (36): 4073–126.doi: 10.1200/JCO.21.01440

  115. Esfahani K, Buhlaiga N, Thébault P, Lapointe R, et al.Alemtuzumab for immune-related myocarditis due toPD-1 therapy. N Engl J Med 2019; 380 (24): 2375-6. doi:10.1056/NEJMc1903064

  116. Salem J-E, Allenbach Y, Vozy A, Brechot N, et al. Abataceptfor severe immune checkpoint inhibitor-associated myocarditis.N Engl J Med 2019; 380 (24): 2377-9. doi: 10.1056/NEJMc1901677

  117. Dolladille C, Ederhy S, Sassier M, Cautela J, et al. Immunecheckpoint inhibitor rechallenge after immune-relatedadverse events in patients with cancer. JAMA Oncol 2020;6 (6): 865-71. doi: 10.1001/jamaoncol.2020.0726

  118. Zhang L, Jones-O’Connor M, Awadalla M, Zlotoff DA, et al.Cardiotoxicity of immune checkpoint inhibitors. Curr TreatOptions Cardiovasc Med 2019; 21 (7): 32. doi: 10.1007/s11936-019-0731-6

  119. Bernhardt AM, Copeland H, Deswal A, Gluck J, GivertzMM; Task Force 1; Task Force 2; Task Force 3; Task Force 4.The International Society for Heart and Lung Transplantation/Heart Failure Society of America Guideline on AcuteMechanical Circulatory Support. J Card Fail 2023; 29 (3):304-74. doi: 10.1016/j.cardfail.2022.11.003

  120. Spillmann F, Van Linthout S, Schmidt G, Klein O, et al.Mode-of-action of the PROPELLA concept in fulminantmyocarditis. Eur Heart J 2019; 40 (26): 2164-69. doi:10.1093/eurheartj/ehz124

  121. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, et al. 2022AHA/ACC/HFSA Guideline for the Management of HeartFailure: A Report of the American College of Cardiology/American Heart Association Joint Committee on ClinicalPractice Guidelines. Circulation 2022; 145 (18): e895-e1032. doi: 10.1161/CIR.0000000000001063

  122. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, etal. 2022 ESC Guidelines for the management of patientswith ventricular arrhythmias and the prevention of suddencardiac death. Eur Heart J 2022; 43 (40): 3997-4126. doi:10.1093/eurheartj/ehac262

  123. Brugada J, Katritsis DG, Arbelo E, Arribas F, et al. 2019 ESCGuidelines for the management of patients with supraventriculartachycardia The Task Force for the management ofpatients with supraventricular tachycardia of the EuropeanSociety of Cardiology (ESC). Eur Heart J 2020; 41 (5): 655-720. doi: 10.1093/eurheartj/ehz467

  124. Hindricks G, Potpara T, Dagres N, Arbelo E, et al. 2020 ESCGuidelines for the diagnosis and management of atrialfibrillation developed in collaboration with the EuropeanAssociation for Cardio-Thoracic Surgery (EACTS): The TaskForce for the diagnosis and management of atrial fibrillationof the European Society of Cardiology (ESC) Developedwith the special contribution of the European HeartRhythm Association (EHRA) of the ESC. Eur Heart J 2021;42 (5): 373-498. doi: 10.1093/eurheartj/ehaa612

  125. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, et al.2021 ESC Guidelines on cardiac pacing and cardiac resynchronizationtherapy. Eur Heart J 2021; 42 (35): 3427-3520.doi: 10.1093/eurheartj/ehab364

  126. Stein-Merlob AF, Rothberg MV, Holman P, Yang EH. Immunotherapy-associated cardiotoxicity of immune checkpointinhibitors and chimeric antigen receptor T cell therapy: Diagnosticand management challenges and strategies. Curr CardiolRep 2021; 23 (3): 11. doi: 10.1007/s11886-021-01440-3




2020     |     www.medigraphic.com